These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 24213148)

  • 21. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Nagler A; Labopin M; Houhou M; Aljurf M; Mousavi A; Hamladji RM; Al Zahrani M; Bondarenko S; Arat M; Angelucci E; Koc Y; Gülbas Z; Sica S; Bourhis JH; Canaani J; Brissot E; Giebel S; Mohty M
    J Hematol Oncol; 2021 Apr; 14(1):53. PubMed ID: 33794963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High expression of Dicer reveals a negative prognostic influence in certain subtypes of primary cutaneous T cell lymphomas.
    Valencak J; Schmid K; Trautinger F; Wallnöfer W; Muellauer L; Soleiman A; Knobler R; Haitel A; Pehamberger H; Raderer M
    J Dermatol Sci; 2011 Dec; 64(3):185-90. PubMed ID: 21937200
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens.
    Bertz H; Illerhaus G; Veelken H; Finke J
    Ann Oncol; 2002 Jan; 13(1):135-9. PubMed ID: 11863095
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term follow up after allogeneic stem cell transplantation in patients with severe aplastic anemia after cyclophosphamide plus antithymocyte globulin conditioning.
    Konopacki J; Porcher R; Robin M; Bieri S; Cayuela JM; Larghero J; Xhaard A; Andreoli AL; Dhedin N; Petropoulou A; Rodriguez-Otero P; Ribaud P; Moins-Teisserenc H; Carmagnat M; Toubert A; Chalandon Y; Socie G; Peffault de Latour R
    Haematologica; 2012 May; 97(5):710-6. PubMed ID: 22180425
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.
    Alanazi W; Chen S; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Al-Shaibani Z; Mattsson J; Michelis FV
    Acta Haematol; 2021; 144(1):66-73. PubMed ID: 32428903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
    Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
    J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcome of allogeneic hematopoietic stem cell transplantation for mycosis fungoides and Sézary syndrome.
    Mori T; Shiratori S; Suzumiya J; Kurokawa M; Shindo M; Naoyuki U; Katsuto T; Miyamoto T; Morishige S; Hirokawa M; Fukuda T; Atsuta Y; Suzuki R
    Hematol Oncol; 2020 Aug; 38(3):266-271. PubMed ID: 32011008
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long term outcomes of nonmyeloablative allogeneic stem cell transplantation with TSEB TLI and ATG for Mycosis Fungoides and Sezary Syndrome.
    Morris SL; Thomas BR; Palanicawandar R; Whittaker S; Child F; Wain M; Sim V; Szydlo R; Mangar S; Olavarria E; Lozano Cerrada S; Muzamil A; Kanfer E
    Bone Marrow Transplant; 2024 Jun; 59(6):874-879. PubMed ID: 38472408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hematopoietic Stem Cell Transplant for Mycosis Fungoides and Sézary Syndrome.
    Virmani P; Zain J; Rosen ST; Myskowski PL; Querfeld C
    Dermatol Clin; 2015 Oct; 33(4):807-18. PubMed ID: 26433851
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sézary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.
    Domingo-Domenech E; Duarte RF; Boumedil A; Onida F; Gabriel I; Finel H; Arcese W; Browne P; Beelen D; Kobbe G; Veelken H; Arranz R; Greinix H; Lenhoff S; Poiré X; Ribera JM; Thompson J; Zuckerman T; Mufti GJ; Cortelezzi A; Olavarria E; Dreger P; Sureda A; Montoto S
    Bone Marrow Transplant; 2021 Jun; 56(6):1391-1401. PubMed ID: 33420392
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect.
    Dodero A; Spina F; Narni F; Patriarca F; Cavattoni I; Benedetti F; Ciceri F; Baronciani D; Scimè R; Pogliani E; Rambaldi A; Bonifazi F; Dalto S; Bruno B; Corradini P
    Leukemia; 2012 Mar; 26(3):520-6. PubMed ID: 21904377
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.
    Dreger P; Brand R; Hansz J; Milligan D; Corradini P; Finke J; Deliliers GL; Martino R; Russell N; Van Biezen A; Michallet M; Niederwieser D;
    Leukemia; 2003 May; 17(5):841-8. PubMed ID: 12750695
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR.
    Sureda A; Zhang MJ; Dreger P; Carreras J; Fenske T; Finel H; Schouten H; Montoto S; Robinson S; Smith SM; Boumedil A; Hamadani M; Pasquini MC
    Cancer; 2018 Apr; 124(8):1733-1742. PubMed ID: 29424927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
    Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF
    Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.
    Schetelig J; Thiede C; Bornhauser M; Schwerdtfeger R; Kiehl M; Beyer J; Sayer HG; Kroger N; Hensel M; Scheffold C; Held TK; Hoffken K; Ho AD; Kienast J; Neubauer A; Zander AR; Fauser AA; Ehninger G; Siegert W;
    J Clin Oncol; 2003 Jul; 21(14):2747-53. PubMed ID: 12860954
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allogeneic hematopoietic stem cell transplantation for heavily pretreated patients with mycosis fungoides and Sezary syndrome.
    Cengiz Seval G; Sahin U; Bozdag SC; Yuksel MK; Topcuoglu P; Akay BN; Sanlı HE; Gurman G; Toprak SK; Ozcan M
    Dermatol Ther; 2022 May; 35(5):e15447. PubMed ID: 35289037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Thymoglobulin by Stem Cell Source (Peripheral Blood Stem Cell or Bone Marrow) After Myeloablative Stem Cell Transplantation From HLA 10/10-Matched Unrelated Donors: A Report From the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
    Ravinet A; Cabrespine A; Socié G; Milpied N; Yakoub Agha I; Nguyen S; Michallet M; Menard AL; Maillard N; Mohty M; Suarez F; Huynh A; Marchand T; Deteix C; Cassuto JP; Maury S; Chevallier P; Reman O; Peffault de Latour R; Bay JO
    Transplantation; 2016 Aug; 100(8):1732-9. PubMed ID: 26528768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allogeneic stem cell transplant for treatment of mycosis fungoides and Sezary syndrome: a systematic review and meta-analysis.
    Goyal A; O'Leary D; Foss F
    Bone Marrow Transplant; 2024 Jan; 59(1):41-51. PubMed ID: 37853164
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.
    Yoon JH; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Cho SG
    Hematol Oncol; 2017 Mar; 35(1):17-24. PubMed ID: 25782369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antithymocyte globulin before allogeneic stem cell transplantation for progressive myelodysplastic syndrome: a study from the French Society of Bone Marrow Transplantation and Cellular Therapy.
    Duléry R; Mohty M; Duhamel A; Robin M; Beguin Y; Michallet M; Vigouroux S; Lioure B; Garnier A; El Cheikh J; Bulabois CE; Huynh A; Bay JO; Daguindau E; Ceballos P; Clément L; Dauriac C; Maillard N; Legrand F; Cornillon J; Guillerm G; François S; Lapusan S; Chevallier P; Damaj G; Yakoub-Agha I
    Biol Blood Marrow Transplant; 2014 May; 20(5):646-54. PubMed ID: 24462982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.